{"id": 4, "relation": 0, "prompt": "<e1> Antacids </e1> : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when <e2> Myfortic </e2> was administered alone under fasting conditions.\n\n###\n\n", "completion": " false"}
{"id": 6, "relation": 1, "prompt": "Antacids: Absorption of a single dose of <e1> Myfortic </e1> was decreased when administered to 12 stable renal transplant patients also taking magnesium- <e2> aluminum </e2> containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.\n\n###\n\n", "completion": " true"}
{"id": 12, "relation": 0, "prompt": "Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium- <e1> aluminum </e1> containing <e2> antacids </e2> (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.\n\n###\n\n", "completion": " false"}
{"id": 58, "relation": 1, "prompt": "However, in a drug-drug interaction study, mean <e1> levonorgesterol </e1> AUC was decreased by 15% when coadministered with <e2> mycophenolate mofetil </e2> .\n\n###\n\n", "completion": " true"}
{"id": 25, "relation": 0, "prompt": "<e1> Azathioprine </e1> / <e2> Mycophenolate Mofetil </e2> : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.\n\n###\n\n", "completion": " false"}
{"id": 69, "relation": 1, "prompt": "Drugs which may potentiate the myeloproliferative effects of <e1> Leukine </e1> , such as lithium and <e2> corticosteroids </e2> , should be used with caution.\n\n###\n\n", "completion": " true"}
{"id": 37, "relation": 0, "prompt": "Azathioprine/Mycophenolate Mofetil: Given that <e1> azathioprine </e1> and mycophenolate mofetil inhibit purine metabolism, it is recommended that <e2> Myfortic </e2> not be administered concomitantly with azathioprine or mycophenolate mofetil.\n\n###\n\n", "completion": " false"}
{"id": 96, "relation": 1, "prompt": "Digoxin: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of <e1> digoxin </e1> with the co-administration of 100 mg <e2> sitagliptin </e2> for 10 days.\n\n###\n\n", "completion": " true"}
{"id": 41, "relation": 0, "prompt": "Azathioprine/Mycophenolate Mofetil: Given that azathioprine and <e1> mycophenolate mofetil </e1> inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with <e2> azathioprine </e2> or mycophenolate mofetil.\n\n###\n\n", "completion": " false"}
{"id": 106, "relation": 1, "prompt": "Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug s metabolism by CYP 3A4, it is possible that ketoconazole, <e1> itraconazole </e1> , erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of <e2> mifepristone </e2> ).\n\n###\n\n", "completion": " true"}
{"id": 43, "relation": 0, "prompt": "Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that <e1> Myfortic </e1> not be administered concomitantly with <e2> azathioprine </e2> or mycophenolate mofetil.\n\n###\n\n", "completion": " false"}
{"id": 119, "relation": 1, "prompt": "John s Wort, and certain anticonvulsants (phenytoin, <e1> phenobarbital </e1> , carbamazepine) may induce <e2> mifepristone </e2> metabolism (lowering serum levels of mifepristone).\n\n###\n\n", "completion": " true"}
{"id": 50, "relation": 0, "prompt": "Therefore, do not administer <e1> Myfortic </e1> with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral <e2> activated charcoal </e2> , because of the potential to reduce the efficacy of Myfortic.\n\n###\n\n", "completion": " false"}
{"id": 155, "relation": 1, "prompt": "The following agents may increase certain actions or side effects of <e1> anticholinergic drugs </e1> : amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), <e2> benzodiazepines </e2> , MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " true"}
{"id": 59, "relation": 0, "prompt": "Therefore, it is recommended that oral <e1> contraceptives </e1> are co- administered with <e2> Myfortic </e2> with caution and additional birth control methods be considered.\n\n###\n\n", "completion": " false"}
{"id": 158, "relation": 1, "prompt": "The following agents may increase certain actions or side effects of <e1> anticholinergic drugs </e1> : amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., <e2> meperidine </e2> ), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " true"}
{"id": 63, "relation": 0, "prompt": "Interference of <e1> MPAG </e1> hydrolysis may lead to less <e2> MPA </e2> available for absorption.\n\n###\n\n", "completion": " false"}
{"id": 255, "relation": 1, "prompt": "<e1> Anticholinergic drugs </e1> in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as <e2> corticosteroids </e2> .\n\n###\n\n", "completion": " true"}
{"id": 71, "relation": 0, "prompt": "The interaction of <e1> Streptase </e1> , <e2> Streptokinase </e2> , with other drugs has not been well studied.\n\n###\n\n", "completion": " false"}
{"id": 273, "relation": 1, "prompt": "Concomitant administration of <e1> propranolol </e1> with <e2> phenothiazines </e2> results in increased plasma levels of both drugs.\n\n###\n\n", "completion": " true"}
{"id": 73, "relation": 0, "prompt": "Use of <e1> Anticoagulants </e1> and Antiplatelet Agents -- <e2> Streptase </e2> , Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.\n\n###\n\n", "completion": " false"}
{"id": 307, "relation": 1, "prompt": "Concurrent use of alcohol and other <e1> CNS depression-producing drugs </e1> may increase the CNS depressant effects of <e2> methyprylon </e2> or these other medications.\n\n###\n\n", "completion": " true"}
{"id": 75, "relation": 0, "prompt": "Use of <e1> Anticoagulants </e1> and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with <e2> antiplatelet agents </e2> and anticoagulants, may cause bleeding complications.\n\n###\n\n", "completion": " false"}
{"id": 332, "relation": 1, "prompt": "- Cisapride, pimozide: Other drugs such as <e1> cisapride </e1> or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some <e2> macrolide antibacterials </e2> .\n\n###\n\n", "completion": " true"}
{"id": 90, "relation": 0, "prompt": "Other <e1> short-acting beta adrenergic aerosol bronchodilators </e1> should not be used concomitantly with <e2> MAXAIR AUTOHALER </e2> because they may have additive effects.\n\n###\n\n", "completion": " false"}
{"id": 641, "relation": 1, "prompt": "Because of profound and long lasting inhibition of gastric acid secretion, <e1> pantoprazole </e1> may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, <e2> ampicillin </e2> esters, and iron salts).\n\n###\n\n", "completion": " true"}
{"id": 100, "relation": 0, "prompt": "Although specific drug or food interactions with <e1> mifepristone </e1> have not been studied, on the basis of this drug s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, <e2> erythromycin </e2> , and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).\n\n###\n\n", "completion": " false"}
{"id": 677, "relation": 1, "prompt": "<e1> Posicor </e1> inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and <e2> tricyclic antidepressants </e2> .\n\n###\n\n", "completion": " true"}
{"id": 105, "relation": 0, "prompt": "Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug s metabolism by CYP 3A4, it is possible that ketoconazole, <e1> itraconazole </e1> , <e2> erythromycin </e2> , and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).\n\n###\n\n", "completion": " false"}
{"id": 691, "relation": 1, "prompt": "In vitro data indicate that the phosphorylation of <e1> stavudine </e1> is also inhibited at relevant concentrations by doxorubicin and <e2> ribavirin </e2> .\n\n###\n\n", "completion": " true"}
{"id": 123, "relation": 0, "prompt": "John s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce <e1> mifepristone </e1> metabolism (lowering serum levels of <e2> mifepristone </e2> ).\n\n###\n\n", "completion": " false"}
{"id": 925, "relation": 1, "prompt": "<e1> Sulfoxone </e1> may increase the effects of barbiturates, <e2> tolbutamide </e2> , and uricosurics.\n\n###\n\n", "completion": " true"}
{"id": 127, "relation": 0, "prompt": "If at all possible <e1> guanethidine </e1> should be discontinued well before <e2> minoxidil </e2> is begun.\n\n###\n\n", "completion": " false"}
{"id": 991, "relation": 1, "prompt": "<e1> Paliperidone </e1> may antagonize the effect of <e2> levodopa </e2> and other dopamine agonists.\n\n###\n\n", "completion": " true"}
{"id": 134, "relation": 0, "prompt": "Vindesine can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - <e1> Phenytoin </e1> : can increase seizure activity - <e2> Live virus vaccines </e2> : may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine\n\n###\n\n", "completion": " false"}
{"id": 1017, "relation": 1, "prompt": "Use of <e1> potassium-sparing diuretics </e1> (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with <e2> ACE inhibitors </e2> can increase the risk of hyperkalemia.\n\n###\n\n", "completion": " true"}
{"id": 143, "relation": 0, "prompt": "Vindesine can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the <e1> vaccine </e1> virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - <e2> Mitomycin-C </e2> : may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine\n\n###\n\n", "completion": " false"}
{"id": 1027, "relation": 1, "prompt": "Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or <e1> potassium </e1> supplements concomitantly with <e2> ACE inhibitors </e2> can increase the risk of hyperkalemia.\n\n###\n\n", "completion": " true"}
{"id": 145, "relation": 0, "prompt": "Vindesine can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the <e1> vaccine </e1> virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the <e2> vaccine </e2>\n\n###\n\n", "completion": " false"}
{"id": 1040, "relation": 1, "prompt": "Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving <e1> ACE inhibitors </e1> during therapy with <e2> lithium </e2> .\n\n###\n\n", "completion": " true"}
{"id": 164, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: <e1> amantadine </e1> , antiarrhythmic agents of class I (e.g., <e2> quinidine </e2> ), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 1069, "relation": 1, "prompt": "MAO Inhibitors: The pressor effect of <e1> sympathomimetic pressor amines </e1> is markedly potentiated in patients receiving <e2> monoamine oxidase inhibitors </e2> (MAOI).\n\n###\n\n", "completion": " true"}
{"id": 167, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: <e1> amantadine </e1> , antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., <e2> phenothiazines </e2> ), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 1080, "relation": 1, "prompt": "Use with Other Central Nervous System Depressants: The depressant effects of <e1> morphine </e1> are potentiated by the presence of other CNS depressants such as <e2> alcohol </e2> , sedatives, antihistaminics, or psychotropic drugs.\n\n###\n\n", "completion": " true"}
{"id": 172, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: <e1> amantadine </e1> , antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), <e2> nitrates </e2> and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 1094, "relation": 1, "prompt": "Use of <e1> neuroleptics </e1> in conjunction with oral <e2> morphine </e2> may increase the risk of respiratory depression, hypotension and profound sedation or coma.\n\n###\n\n", "completion": " true"}
{"id": 181, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1> antiarrhythmic agents of class I </e1> (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, <e2> MAO inhibitors </e2> , narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 1119, "relation": 1, "prompt": "The induction dose requirements of <e1> DIPRIVAN </e1> Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and <e2> fentanyl </e2> , etc.)\n\n###\n\n", "completion": " true"}
{"id": 183, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1> antiarrhythmic agents of class I </e1> (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., <e2> meperidine </e2> ), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 1415, "relation": 1, "prompt": "The concomitant use of <e1> Sanctura </e1> with other <e2> anticholinergic agents </e2> that produce dry mouth, constipation, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects.\n\n###\n\n", "completion": " true"}
{"id": 186, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1> antiarrhythmic agents of class I </e1> (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, <e2> sympathomimetic agents </e2> , tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 1430, "relation": 1, "prompt": "Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, <e1> Sanctura </e1> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and <e2> tenofovir </e2> ).\n\n###\n\n", "completion": " true"}
{"id": 201, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), <e1> antihistamines </e1> , antipsychotic agents (e.g., phenothiazines), <e2> benzodiazepines </e2> , MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 1453, "relation": 1, "prompt": "Preliminary evidence suggests that <e1> cimetidine </e1> inhibits <e2> mebendazole </e2> metabolism and may result in an increase in plasma concentrations of mebendazole.\n\n###\n\n", "completion": " true"}
{"id": 205, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), <e1> antihistamines </e1> , antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), <e2> nitrates </e2> and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 1519, "relation": 1, "prompt": "<e1> Nifedipine </e1> AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state <e2> MYCAMINE </e2> compared with nifedipine alone.\n\n###\n\n", "completion": " true"}
{"id": 207, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), <e1> antihistamines </e1> , antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, <e2> sympathomimetic agents </e2> , tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 1550, "relation": 1, "prompt": "Coadministration with a high dose of <e1> antacid </e1> (170 mEq) results in a 28% decrease in plasma concentrations of <e2> ranitidine </e2> and may decrease plasma concentrations of bismuth from TRITEC.\n\n###\n\n", "completion": " true"}
{"id": 215, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, <e1> antipsychotic agents </e1> (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and <e2> nitrites </e2> , sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 1551, "relation": 1, "prompt": "Coadministration with a high dose of <e1> antacid </e1> (170 mEq) results in a 28% decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from <e2> TRITEC </e2> .\n\n###\n\n", "completion": " true"}
{"id": 217, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, <e1> antipsychotic agents </e1> (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, <e2> tricyclic antidepressants </e2> , and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 1580, "relation": 1, "prompt": "Prior administration of <e1> succinylcholine </e1> can potentiate the neuromuscular blocking effects of <e2> nondepolarizing agents </e2> .\n\n###\n\n", "completion": " true"}
{"id": 228, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), <e1> benzodiazepines </e1> , MAO inhibitors, narcotic analgesics (e.g., <e2> meperidine </e2> ), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 1841, "relation": 1, "prompt": "Fenofibrate: In a pharmacokinetic study, concomitant <e1> fenofibrate </e1> administration increased total <e2> ezetimibe </e2> concentrations approximately 1.5-fold.\n\n###\n\n", "completion": " true"}
{"id": 230, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), <e1> benzodiazepines </e1> , MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and <e2> nitrites </e2> , sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 1868, "relation": 1, "prompt": "Cyclosporine: The total <e1> ezetimibe </e1> level increased 12-fold in one renal transplant patient receiving multiple medications, including <e2> cyclosporine </e2> .\n\n###\n\n", "completion": " true"}
{"id": 234, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, <e1> MAO inhibitors </e1> , narcotic analgesics (e.g., <e2> meperidine </e2> ), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 1904, "relation": 1, "prompt": "<e1> Salicylate </e1> competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, <e2> warfarin </e2> , methotrexate, and possibly corticosteroids.\n\n###\n\n", "completion": " true"}
{"id": 237, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, <e1> MAO inhibitors </e1> , narcotic analgesics (e.g., meperidine), nitrates and nitrites, <e2> sympathomimetic agents </e2> , tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 1957, "relation": 1, "prompt": "<e1> Triprolidine </e1> may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, <e2> narcotic analgesics </e2> , sedatives, and tranquillisers.\n\n###\n\n", "completion": " true"}
{"id": 239, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, <e1> narcotic analgesics </e1> (e.g., <e2> meperidine </e2> ), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 1985, "relation": 1, "prompt": "The effects of anticholinergic drugs, such as <e1> atropine </e1> and tricyclic antidepressants may be enhanced by the concomitant administration of <e2> triprolidine </e2> .\n\n###\n\n", "completion": " true"}
{"id": 243, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, <e1> narcotic analgesics </e1> (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, <e2> tricyclic antidepressants </e2> , and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 1991, "relation": 1, "prompt": "The use of <e1> AGGRASTAT </e1> , in combination with heparin and <e2> aspirin </e2> , has been associated with an increase in bleeding compared to heparin and aspirin alone (see\n\n###\n\n", "completion": " true"}
{"id": 252, "relation": 0, "prompt": "The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and <e1> nitrites </e1> , sympathomimetic agents, <e2> tricyclic antidepressants </e2> , and other drugs having anticholinergic activity.\n\n###\n\n", "completion": " false"}
{"id": 2009, "relation": 1, "prompt": "In clinical studies of TOBI, patients taking <e1> TOBI </e1> concomitantly with dornase alfa (PULMOZYME , Genentech), <e2> (beta)-agonists </e2> , inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.\n\n###\n\n", "completion": " true"}
{"id": 260, "relation": 0, "prompt": "DRUG INTERACTIONS There are no known drug/drug interactions with oral <e1> ALKERAN </e1> Vaccinations with live organism vaccines are not recommended in immunocompromised individuals <e2> Nalidixic acid </e2> together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.\n\n###\n\n", "completion": " false"}
{"id": 2012, "relation": 1, "prompt": "In clinical studies of TOBI, patients taking <e1> TOBI </e1> concomitantly with dornase alfa (PULMOZYME , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral <e2> aminoglycosides </e2> demonstrated adverse experience profiles similar to the study population as a whole.\n\n###\n\n", "completion": " true"}
{"id": 263, "relation": 0, "prompt": "DRUG INTERACTIONS There are no known drug/drug interactions with oral ALKERAN Vaccinations with <e1> live organism vaccines </e1> are not recommended in immunocompromised individuals Nalidixic acid together with high-dose intravenous <e2> melphalan </e2> has caused deaths in children due to haemorrhagic enterocolitis.\n\n###\n\n", "completion": " false"}
{"id": 2161, "relation": 1, "prompt": "These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of <e1> DIFLUCAN </e1> with oral <e2> hypoglycemic agents </e2> ;\n\n###\n\n", "completion": " true"}
{"id": 270, "relation": 0, "prompt": "The concurrent use of streptozocin and <e1> phenytoin </e1> has been reported in one case to result in reduced <e2> streptozocin </e2> cytotoxicity.\n\n###\n\n", "completion": " false"}
{"id": 2181, "relation": 1, "prompt": "Phenytoin: <e1> DIFLUCAN </e1> increases the plasma concentrations of <e2> phenytoin </e2> .\n\n###\n\n", "completion": " true"}
{"id": 275, "relation": 0, "prompt": "Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as <e1> amphotericin B </e1> , <e2> aminoglycosides </e2> , bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.\n\n###\n\n", "completion": " false"}
{"id": 2233, "relation": 1, "prompt": "This effect on <e1> midazolam </e1> appears to be more pronounced following oral administration of <e2> fluconazole </e2> than with fluconazole administered intravenously.\n\n###\n\n", "completion": " true"}
